Childhood cancer survivors face heightened risks of chronic kidney disease and hypertension, necessitating urgent updates to ...

M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill, shares promising results of ensifentrine in helping patients with insufficient chronic obstructive ...

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background ...

International Conference used FDA-approved tools to see how sleep can impact other parts of recovery for patients in the ...

Margrit Wiesendanger, MD, PhD, explores lupus symptoms, diagnosis challenges, and the importance of early detection to prevent inflammation-related damage.

Treatment options for children with hemophilia A have expanded with the FDA approval of Bayer's Jivi antihemophilic factor ...

Over 500,000 US patients hospitalized with nonsevere COVID-19 saw no clinically significant benefit and potential harm ...

The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD) ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Sanjay Ramakrishnan, MD, senior lecturer, University of Western Australia, discusses the value of the win ratio approach in evaluating treatment effects in chronic obstructive pulmonary disease (COPD) ...